Acupuncture combined with massage at meridian points for assisted endocrine therapy-related hot flashes in breast cancer: a randomized, controlled, blind, prospective clinical study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900024831

Enrollment

Unknown

Registered

2019-07-29

Start date

2019-09-01

Completion date

Unknown

Last updated

2019-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

endocrine therapy-related hot flashes

Interventions

Group 1:acupuncture combined with massage at meridian points

Group 2:no intervention

Eligibility

Sex/Gender

Female

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age older than (including) 18 years, less than (including) 75 years; 2. Hormone receptor positive breast cancer patients; 3. Use EP at least 30 days before the study, and plan to continue treatment during the study period; 4. After EP use, the following symptoms begin to appear or aggravate: hot flashes, can be accompanied by night sweating, insomnia, fatigue, depression, loss of libido, quality of life. Amount decreased; 5. Patients with hot flashes: frequency of hot flashes (> 3 times per day); 6. KPS > 70 points, ECOG physical state 0-2 points.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women, or those who have fertility requirements in the past six months; 2. Acupuncture and moxibustion treatment for adverse endocrine symptoms in the first three months of the study; 3. Drug therapy for menopausal symptoms (such as systemic phytoestrogen, tebron or similar substances, venlaxine or specific homeopathic drugs) is currently being used; 4. Research process Patients planning to undergo surgery, chemotherapy, radiotherapy and immunotherapy; 5. History of other malignant tumors in the past five years; 6. Severe coagulation dysfunction; 7. History of cardiovascular, liver, respiratory, kidney, blood and endocrine diseases with clinical symptoms; 8. Mental or cognitive impairment; 9. Researchers do not consider it appropriate to participate.

Design outcomes

Primary

Measure	Time frame
hot flash score;	—

Secondary

Measure	Time frame
timing of hot flash;Severity of sweating;Kupperman;Functional Assessment of Cancer Therapy-Breast cancer;	—

Countries

China

Contacts

Public ContactXue Mingxin

The First Affiliated Hospital of Nanjing Medical University, Jiangsu Privnce Hospital

jshtcmxmx@sina.com+86 13952099299

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026